<DOC>
	<DOCNO>NCT02416076</DOCNO>
	<brief_summary>Up 40 subject enrol , randomize treat . Enrolled subject receive one , split-face Ulthera® treatment face neck use standard transducer one side face simulines transducer side face . Follow-up visit occur 90 180 day post-treatment . Study image obtain pre-treatment , immediately post-treatment , follow-up visit .</brief_summary>
	<brief_title>Ultherapy® Treating Face Neck Using Standard Versus Simulines Transducers</brief_title>
	<detailed_description>This prospective , multi-center , split-face , randomized pilot trial determine clinical feasibility simulines transducer , i.e. , transducer deliver two line treatment simultaneously ( ) , comparison standard transducer deliver single treatment line , collect average pain score treat region , well efficacy treatment efficiency data . There 3 study arm arm 2 treatment group . Enrolled subject randomize one two study arm , one two treatment group within study arm.to determine side face treat standard transducer simulines transducer energy level treatment . Subjects receive one dual-depth treatment 4.5mm 3.0mm depth . Clinical feasibility assess base comfort level standard transducer versus simulines transducer compare average pain score obtain study treatment . Efficacy determine base qualitative masked assessment post-treatment photograph compare pre-treatment photograph quantitative eyebrow lift measurement . Patient satisfaction questionnaire obtain .</detailed_description>
	<mesh_term>Cutis Laxa</mesh_term>
	<criteria>Male female , age 30 65 year . Subject good health . Skin laxity area ( ) treat . Understands accepts obligation undergo procedure area treat follow‐up period . Willingness ability comply protocol requirement , include return follow‐up visit abstain exclusionary procedure duration study . Subjects childbearing potential must negative urine pregnancy test result must lactate Screening Visit willing able use acceptable method birth control ( e.g . barrier method use spermicidal agent , hormonal method , IUD , surgical sterilization , abstinence ) study . Women consider childbearing potential one follow condition document medical history : 1 . Postmenopausal least 12 month prior study ; 2 . Without uterus and/or ovary ; 3 . Bilateral tubal ligation least six month prior study enrollment . Absence physical psychological condition unacceptable investigator . Willingness refrain use aspirin , Ibuprofen , Naproxen NSAID prior study treatment chronic use entire posttreatment study period . Washout period , chronic user , 4 week prior first treatment . Washout period limit acute NSAID use , i.e. , maximum 2‐3 dos , require 2 week prior study treatment visit . Willingness ability provide write consent study‐required photography adherence photography procedure ( i.e. , removal jewelry makeup ) . Willingness ability provide write informed consent HIPAA authorization prior performance study‐related procedure . Presence active systemic local skin disease may affect wound healing . Severe solar elastosis . Excessive subcutaneous fat area ( ) treat . Excessive skin laxity area ( ) treat . Significant scarring area ( ) treat . Open wound lesion area ( ) treat . Severe cystic acne area ( ) treat . Active implant ( e.g. , pacemaker defibrillator ) , metallic implant treatment area ( dental implant include ) . Inability understand protocol give inform consent . Microdermabrasion , prescription level glycolic acid treatment treatment area ( ) within two week prior study participation study . Marked asymmetry , ptosis , excessive dermatochalasis , deep dermal scarring , thick sebaceous skin area ( ) treat . BMI equal great 25 . History chronic drug alcohol abuse . History autoimmune disease . Concurrent therapy , investigator 's opinion , would interfere evaluation safety efficacy study device . Subjects anticipate need surgery overnight hospitalization study . Subjects , investigator 's opinion , history poor cooperation , noncompliance medical treatment , unreliability . Concurrent enrollment study involve use investigational device drug . Current smoker history smoking last five year . Current user nicotine‐containing product , e.g. , e‐cigarettes , Nicorette gum , nicotine patch , etc . History follow cosmetic treatment area ( ) treat : 1 . Skin tighten procedure within past year ; 2 . Injectable filler type within past : i.12 month Hyaluronic acid filler ( e.g . Rstylane ) ii.12 month Ca Hydroxyapatite filler ( e.g . Radiesse ) iii . 24 month Poly‐L‐Lactic acid filler ( e.g . Sculptra ) iv . Ever permanent filler ( e.g . Silicone , ArteFill ) c. Neurotoxins within past six month ; d. Ablative resurface laser treatment ; e. Nonablative , rejuvenative laser light treatment within past six month ; f. Surgical dermabrasion deep facial peel ; g. Facelifts , blepharoplasty , browlift within past 18 month ; h. Any history contour thread . History use follow prescription medication : 1 . Accutane systemic retinoids within past six month ; 2 . Topical Retinoids within past two week ; 3 . Antiplatelet agents/Anticoagulants ( Coumadin , Heparin , Plavix ) ; 4 . Psychiatric drug investigator opinion would impair subject understand protocol requirement understand signing informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Ulthera® System</keyword>
	<keyword>Ultherapy®</keyword>
	<keyword>Ulthera , Inc .</keyword>
</DOC>